Urologic oncologist & surgeon; Chairman, Department of Urology, Pediatric Urology and Urooncology, University Hospital Essen
Essen, Deutschland
Joined October 2018
- Tweets606
- Following163
- Followers622
- Likes3.1K
Perioperative Apalutamide in High-Risk Localized Prostate Cancer | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
Honored to be involved - lots to discuss and lots to come
It adds data to the discussion. The RP only substudy comes next year.
SPCG15 will be very important.
Primary PET staging not available in PROTEUS.
Comparison to ENZARAD and ATLAS will be interesting…
I am very happy that PROTEUS is positive.
Boris Hadaschik retweeted
New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study
thelancet.com/journals/lanon…
In an international registry study of 11,154 patients, investigators developed PPP3 nomograms integrating clinical features and PSMA-PET PROMISE metrics to predict 3-, 5-, and 7-year overall survival in #ProstateCancer
Developed and validated across 35 global sites,
✅ Models demonstrated strong discrimination (C-index ~0.83–0.84).
✅PPP3 performed as well as or better than existing clinical risk scores, supporting PSMA-PET–based risk stratification for guidelines, clinical decision-making, and trial design.
@CalaisJeremie
@DrMHofman
@thomashopemd
@drlouiseemmett
@DrAGafita
@ProfKHerrmann
@ProfHadaschik
@Dr_K_Rahbar
@bjartell
@OncoAlert 🚨
@silkegillessen
@AOmlin
@weoncologists
#EAU26
back on X for scientific reasons because the alternative platforms unfortunately did not fulfill my expectations
Boris Hadaschik retweeted
PEACE-1 RT is now published online at @TheLancet
Some differences with STAMPEDE
Key messages: RT to prostate in M1 #prostatecancer
1. improves rPFS but not OS in low volume
2. improves CRPC-FS & reduces serious GU SAE irrespective of volume
Full text: thelancet.com/journals/lance…
Happy to share: Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer - ScienceDirect sciencedirect.com/science/ar…
Boris Hadaschik retweeted
We are very proud that the paper is online! Sincere thanks to our scientific committee and all panellists. Manuscript is open access, please use and distribute it! Hope to see you at the first edition of @APCCC_Lugano Diagnostics @ProfKHerrmann @stefanofanti4
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24
LINK TO ARTICLE👇👇👇👇👇👇👇👇
sciencedirect.com/science/ar…
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking.
The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting.
The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer.
Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore
Eric Small
Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis
Ana Aparicio
Andrew J. Armstrong
Diogo Assed Bastos
Gerhardt Attard
Karol Axcrona
Mouna Ayadi
Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul
Consuelo Buttigliero
Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng
Kim N. Chi
Caroline S. Clarke
Noel Clarke
Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke
Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun
Felix Y. Feng
Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis
Susan Halabi
Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope
Lisa G. Horvath
Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones
Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal
Fernando C. Maluf 75 76,
@quimmateo
David Matheson 78,
Mika P. Matikainen 79,
Ray McDermott 80,
@DrRanaMcKay
Niven Mehra 82,
@amerseburger
@CaPsurvivorship ,
Michael J. Morris 85,
Hind Mrabti 86,
Deborah Mukherji
@declangmurphy
Vedang Murthy
Shingai B.A. Mutambirwa
@DrPaulNguyen
William K. Oh
@piet_ost
Joe M. O’Sullivan
Anwar R. Padhani
Chris Parker
Darren M.C. Poon
Colin C. Pritchard
Danny M Rabah
Dana Rathkopf
Robert E. Reiter
Raphaele Renard-Penna
Charles J. Ryan
Fred Saad
Juan Pablo Sade
Shahneen Sandhu
Oliver A. Sartor
Edward Schaeffer
Howard I. Scher
Nima Sharifi
Iwona A. Skoneczna
Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki
Mary-Ellen Taplin
Camilla Thellenberg-Karlsson
Derya Tilki
Levent N. Türkeri
Hiroji Uemura
@DrYukselUrun
Claire L. Vale
Neha Vapiwala
Jochen Walz
Kosj Yamoah
Dingwei Ye
Evan Y. Yu
Almudena Zapatero
@AOmlin
Boris Hadaschik retweeted
Delighted to share our latest on #18F_PSMA_PET just published in cool new @JUOpenPlus!
•n=1335 scans from 1220 men
•1°: PSMA 96% vs MRI 89% sens. for pros lesions at RP
•2°: PSA 0.2-0.49 post RP/RT ➡️ avidity in 57.8%
BUT high false +ves (esp ribs)
journals.lww.com/juop/fullte…
Boris Hadaschik retweeted
Sharing key takeaways from my #ASTRO2024 presentation! I'm grateful for the support I've received—thank you, @ASTRO, @MGHCancerCenter @theNCI & @Pcfnews. It’s a win for our field that both #ProtonTherapy & #IMRT are equally highly effective for localized #ProstateCancer.
Boris Hadaschik retweeted
🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in @Nature! nature.com/articles/s41586-0…
ALT Artistic conceptualization of chromosomal DNA breakdown and extrachromosomal circular DNA (ecDNA). These ecDNA circles can drive resistance to therapy in bladder cancer. Credit: Ella Maru Studio, Inc. @Ella_Maru
Boris Hadaschik retweeted
Our latest paper on risk stratified prostate cancer testing - TARGET study, a simultaneous evaluation of PRS, PSAd, F/T PSA, phi in a PSA triggered MRI diagnostic pathway + testing different defn of ‘clinical significance’ link.springer.com/10.1186/s1…
Boris Hadaschik retweeted
In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: nej.md/4dBI8UN
ALT A graph showing disease-free survival.
Boris Hadaschik retweeted
Outstanding presentation by @drjefstathiou #ASTRO24 showing no improvement in any outcome with proton therapy for localised prostate cancer compared to photon therapy. Congratulations to all authors! 👏
Boris Hadaschik retweeted
the study did not show a meaningful difference. DFS was improved in pts with higher risk of recurrence, such as sRCC, PDL1+ or T4. Getting patient populations right is of clinical interest and leads to stronger recommendations in these groups of patients in my daily practice
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial out on @JCO_ASCO
The CheckMate 914 ♟️trial is a phase III study that evaluated the efficacy of adjuvant nivolumab🧪 monotherapy (part B) versus placebo in patients with localized renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy. #KidneyCancer
In this randomized trial of 825 patients, the primary endpoint of disease-free survival (DFS) per blinded independent central review (BICR) was not met, with a hazard ratio (HR) of 0.87 (95% CI, 0.62 to 1.21; P = .40). Although the 18-month DFS rates were slightly higher in the nivolumab group (78.4% vs. 75.4% for placebo), the difference was not statistically significant. Adverse events, particularly grade 3-4 events, were more common with nivolumab plus ipilimumab, leading to higher treatment discontinuation rates.
Overall, the study did not demonstrate a DFS benefit for nivolumab in this patient population.
ascopubs.org/doi/full/10.120…
@motzermd
@YoshihikoTomita
@HernanJCutuli
@grimm_mo
@JeffreyCGoh1
@BrianShuch
@ViktorGruenwald
#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco @heinrich_kat @niklas_kluemper
Boris Hadaschik retweeted
After 4 years of the GÖTEBORG-2 trial, MRI-targeted biopsy led to less detection of clinically insignificant prostate cancer than systematic biopsy without compromising the detection of cancer that may affect survival. Read the full trial results: nej.md/4ewOjKT
ALT Graphs of the cumulative incidence of detection of clinically insignificant prostate cancer, clinically significant prostate cancer, and advanced or high-risk prostate cancer.
Boris Hadaschik retweeted
Words of Wisdom Wednesday: Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer by @niklas_kluemper, @fverabadillo, @Markuseckstein3, @ProfHadaschik and @ViktorGruenwald
Read the full article here: buff.ly/47kxeS9
#UroSoMe #MedTwitter #UrothelialCancer #EurUrol #WordsofWisdomWednesday
Boris Hadaschik retweeted
Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone.
Full NIAGARA trial results: nej.md/4gmAqk3 #ESMO24
